United States sues WPATH over pediatric treatment claims
Tap title to read story
The U.S. Federal Trade Commission has filed a federal lawsuit against the World Professional Association for Transgender Health (WPATH), alleging deceptive marketing of pediatric gender-affirming medical interventions. Coordinating with attorneys general from Alaska, Iowa, Nebraska, and Texas, the FTC claims WPATH promoted puberty blockers, cross-sex hormones, and irreversible surgeries for minors as safe and medically necessary without adequate scientific support. The complaint, filed on June 17, 2026, further alleges WPATH failed to disclose serious, potentially permanent risks including infertility and loss of sexual function. The case marks a notable expansion of FTC consumer protection authority into medical guidelines and standards of care.
More context
Timeline
- Historically, FTC targets commercial consumer fraud
- Historically, FTC enforces against deceptive advertising
- Historically, WPATH develops transgender health guidelines
- Jun 17, 2026 FTC files federal lawsuit
- Jun 17, 2026 four state attorneys general join
- Jun 17, 2026 complaint alleges deceptive medical marketing
- Jun 17, 2026 lawsuit cites undisclosed permanent treatment risks
- After filing, case signals expanded healthcare oversight
Why it matters
This lawsuit affects healthcare and family. It questions the safety and necessity of certain treatments for transgender minors. If you're a parent, it's a reminder to research and discuss potential risks with doctors.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
